KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Receivables (2016 - 2025)

Idexx Laboratories (IDXX) has 17 years of Receivables data on record, last reported at $628.2 million in Q4 2025.

  • For Q4 2025, Receivables rose 17.57% year-over-year to $628.2 million; the TTM value through Dec 2025 reached $628.2 million, up 17.57%, while the annual FY2025 figure was $628.2 million, 17.57% up from the prior year.
  • Receivables reached $628.2 million in Q4 2025 per IDXX's latest filing, down from $638.8 million in the prior quarter.
  • Across five years, Receivables topped out at $638.8 million in Q3 2025 and bottomed at $406.1 million in Q4 2021.
  • Average Receivables over 5 years is $508.6 million, with a median of $507.8 million recorded in 2023.
  • Peak YoY movement for Receivables: increased 28.16% in 2021, then increased 4.25% in 2024.
  • A 5-year view of Receivables shows it stood at $406.1 million in 2021, then grew by 8.95% to $442.5 million in 2022, then increased by 15.84% to $512.6 million in 2023, then rose by 4.25% to $534.3 million in 2024, then increased by 17.57% to $628.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $628.2 million in Q4 2025, $638.8 million in Q3 2025, and $628.5 million in Q2 2025.